|
| 36094848 | Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry. | Blood Adv | 2023 |
| 37944179 | Introduction to a review series on RNA therapeutics in hematology. | Blood | 2023 |
| 37572755 | The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT. | J Allergy Clin Immunol Pract | 2023 |
| 37498362 | Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. | Blood Cancer Discov | 2023 |
| 37601878 | Incidence of blast phase in myelofibrosis according to anemia severity. | EJHaem | 2023 |
| 35381066 | Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations. | Blood Adv | 2023 |
| 37315179 | Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. | Blood Adv | 2023 |
| 37283522 | The international consensus classification of eosinophilic disorders and systemic mastocytosis. | Am J Hematol | 2023 |
| 37076693 | Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. | Leukemia | 2023 |
| 37165840 | Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. | Haematologica | 2023 |
| 36403897 | Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis. | J Allergy Clin Immunol Pract | 2023 |
| 36712071 | Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens. | bioRxiv | 2023 |
| 34533850 | World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. | Am J Hematol | 2022 |
| 35767897 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. | Blood | 2022 |
| 35342031 | Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. | J Allergy Clin Immunol Pract | 2022 |
| 35763665 | Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. | Blood | 2022 |
| 35640224 | Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. | Blood Adv | 2022 |
| 35790816 | Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. | Leukemia | 2022 |
| 35724950 | Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium. | J Allergy Clin Immunol Pract | 2022 |
| 35430191 | Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. | J Allergy Clin Immunol | 2022 |
| 35724949 | Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group. | J Allergy Clin Immunol Pract | 2022 |
| 35724948 | Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis. | J Allergy Clin Immunol Pract | 2022 |
| 35421448 | Drug-induced mast cell eradication: AÂ novel approach to treat mast cell activation disorders? | J Allergy Clin Immunol | 2022 |
| 35717689 | Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. | Leuk Res | 2022 |
| 35751150 | Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study. | Br J Haematol | 2022 |
| 35623575 | Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. | J Allergy Clin Immunol Pract | 2022 |
| 35747843 | European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. | Hemasphere | 2022 |
| 36485158 | Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. | Hematology Am Soc Hematol Educ Program | 2022 |
| 36075392 | Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36042316 | Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. | Leukemia | 2022 |
| 35877999 | Avapritinib for advanced systemic mastocytosis. | Blood | 2022 |
| 35283331 | Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. | J Allergy Clin Immunol Pract | 2022 |
| 35271702 | Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. | Blood | 2022 |
| 35235417 | Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis. | J Clin Oncol | 2022 |
| 34545185 | Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. | Leukemia | 2022 |
| 32334853 | Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. | Blood Rev | 2021 |
| 33491527 | Routine use of gemtuzumab ozogamicin in 7â¿¿+â¿¿3-based inductions for all 'non-adverse' risk AML. | Leuk Lymphoma | 2021 |
| 33508247 | Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. | Lancet Haematol | 2021 |
| 33804174 | Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. | Int J Mol Sci | 2021 |
| 33581142 | Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. | J Invest Dermatol | 2021 |
| 33831618 | COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). | J Allergy Clin Immunol Pract | 2021 |
| 33745886 | Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. | J Allergy Clin Immunol | 2021 |
| 34944883 | Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. | Cancers (Basel) | 2021 |
| 34873345 | Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. | Nat Med | 2021 |
| 34873347 | Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. | Nat Med | 2021 |
| 34901755 | Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. | Hemasphere | 2021 |
| 34496019 | A novel activating JAK1 mutation in chronic eosinophilic leukemia. | Blood Adv | 2021 |
| 34755136 | Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. | Cell Rep Med | 2021 |
| 34454676 | Current and future status of JAK inhibitors. | Lancet | 2021 |
| 34505882 | Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. | Blood Adv | 2021 |